Consequently, we launched this investigation to evaluate the therapeutic benefit and tolerability of sintilimab, a PD‐(L)1–blocking monoclonal antibody, together with the oral multi‐target anti‐angiogenesis agent anlotinib in metastatic NSCLC individuals experiencing progression after first‐line PD‐(L)1 inhibition. This evidence concerns the gene CD274 and non-small cell lung carcinoma.